vendredi 18 octobre 2019

Onco Actu du 18 otobre 2019


1. BIOLOGIE



The big picture of a microscopic event [Garvan Institute]











1.4 BIOLOGIE - TECHNOS, MODÈLES



Imaging combined with genetic screening of cells enhances genomic discoveries [Broad Institute]











3.1 PRÉVENTION - TABAC



Tobacco Use and Tobacco-Related Behaviors — 11 Countries, 2008–2017 [CDC]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Juul Suspends Online Sales of Flavored E-Cigarettes [NY Times]










Juul halts all U.S. sales of many flavored nicotine liquids [Reuters]











U.S. ramps up testing in search of vaping illness cause as cases near 1,500 [Reuters]











4.2 DÉP., DIAG. & PRONO. - GÉNOME



Competitor accuses 23andMe of ‘false negatives’ in cancer-gene testing [STAT]










Researchers Quantify Limitations of Health Reports from Direct-to-Consumer Genetic Tests [ASHG]











Genetic testing kits 'may wrongly reassure those at risk of cancer' [The Guardian]











4.9 DÉP., DIAG. & PRONO. - SEIN



Breast Cancer Genetic Testing for All Women? [DNA Science Blog]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Researchers identify targeted therapy that can help children with deadly nerve cancer [EurekAlert!]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



ArsenalBio joins next-gen cell therapy field with $85M A round [Fierce Biotech]











Sean Parker helps create a CRISPRed cell therapy 2.0 play — and he’s got a high-profile set of leaders on the team [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



MD Anderson and Varian partner to optimize radiation oncology treatment [MD Anderson Cancer Center]











5.2 PHARMA



AstraZeneca and Daiichi get Q2 2020 PDUFA date for breast cancer ADC [Fierce Biotech]











The FDA will hustle up an expedited review for AstraZeneca’s next shot at a blockbuster cancer drug franchise [EndPoints]











AstraZeneca breast cancer treatment gets FDA priority review [Reuters]











5.2.6 PHARMA - BIOTECH



Syros cans solid tumor drug after seeing early clinical data [Fierce Biotech]











Protein-degrading Plexium debuts with $28M to attack cancer, neurodegenerative disease [Fierce Biotech]











Mirati preps its first look at their KRAS G12C contender, and they have to clear a high bar for success [EndPoints]











5.4 TRAITEMENTS - ECONOMIE



Targeted breast cancer treatment approved for NHS use in England [Cancer Research UK]











6.10.1 POLITIQUES (USA)



$3 billion ballot proposition will decide fate of Texas cancer research funding agency [Science]











6.11 PATIENTS



Starting Chemotherapy, When You’re Ready [NY Times]